Fast Five Quiz: Test Your Knowledge of Mantle Cell Lymphoma

Elwyn C Cabebe, MD; Winston W. Tan, MD; Ann S. LaCasce, MD, MMSc


January 09, 2023

The clinical course of the disease can be highly variable, and prognosis is dependent on multiple factors, including time to progression of disease. Relapse within 12 months after initial therapy or within 24 months of diagnosis is associated with poor prognosis.

Age and performance status are important considerations in selection of initial therapy. Other factors in determination of first-line therapy include stage, TP53 mutation status, eligibility for transplant, and presence of high-risk disease and availability of clinical trials.

While the optimal regimen for initial therapy has not yet been determined, treatment with a single alkylating agent is not recommended, even in older or unfit patients. Surgery does not play a role in the treatment of MCL.

Learn more about MCL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.